Rong Wang, PhD
Senior Research Scientist in EpidemiologyDownloadHi-Res Photo
Cards
Contact Info
About
Titles
Senior Research Scientist in Epidemiology
Biography
Dr. Wang is a cancer epidemiologist who studies the health outcomes and etiology of different types of cancers, especially hematopoietic malignancies. She is interested in the pattern of care, treatment and cost in older adults. She is also working on traffic exposure and genetic characteristics on the risk of cancer.
Appointments
Chronic Disease Epidemiology
Senior Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- Yale University (2008)
Research
Overview
Medical Subject Headings (MeSH)
Biostatistics; Chronic Disease; Epidemiology; Health Care; Neoplasms
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rong Wang's published research.
Publications Timeline
A big-picture view of Rong Wang's research output by year.
Research Interests
Research topics Rong Wang is interested in exploring.
Xiaomei Ma, PhD
Nikolai Podoltsev, MD, PhD
Amer Zeidan, MBBS
Scott Huntington, MD, MPH, MSc
Cary Gross, MD
Jan Philipp Bewersdorf, MD
103Publications
1,711Citations
Neoplasms
Chronic Disease
Publications
2024
Disparities in Colorectal Cancer Screening Before and After the Onset of the COVID Pandemic
Siddique S, Wang R, Gaddy J, Stempel J, Warren J, Gross C, Ma X. Disparities in Colorectal Cancer Screening Before and After the Onset of the COVID Pandemic. Journal Of General Internal Medicine 2024, 1-9. PMID: 39495455, DOI: 10.1007/s11606-024-09153-3.Peer-Reviewed Original ResearchConceptsRisk of CRCSocioeconomic statusCRC screeningArea-level socioeconomic measuresArea-level socioeconomic factorsHigher risk of CRCArea residentsColorectal cancer screeningSocial deprivation indexHigher socioeconomic statusLow socioeconomic statusEthnic minoritized populationsDifference-in-differences analysisPost-onset periodDesignRetrospective cohort studyDeprivation indexCancer screeningSocioeconomic measuresPrivately insured individualsMetropolitan area residentsCOVID pandemicScreen useAverage riskCompare disparitiesSocioeconomic factorsUSPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years
Siddique S, Wang R, Yasin F, Gaddy J, Zhang L, Gross C, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Network Open 2024, 7: e2436358. PMID: 39361285, PMCID: PMC11450516, DOI: 10.1001/jamanetworkopen.2024.36358.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsUS Preventive Services Task ForceUS Preventive Services Task Force recommendationsColorectal cancer screening uptakeAverage-risk individualsScreening uptakeHigher socioeconomic statusSocioeconomic statusScreening recommendationsColorectal cancerColorectal cancer screening recommendationsPreventive Services Task ForceCohort studyCancer screening recommendationsScreening uptake ratesInterrupted time series analysisLow socioeconomic statusPrivate insurance beneficiariesScreening ratesSocioeconomic disparitiesRetrospective cohort studyMain OutcomesPotential disparitiesEvaluate changesClaims dataAbsolute changeAssociations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchCitationsConceptsLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosisHigh ambient temperature in pregnancy and risk of childhood acute lymphoblastic leukaemia: an observational study
Rogne T, Wang R, Wang P, Deziel N, Metayer C, Wiemels J, Chen K, Warren J, Ma X. High ambient temperature in pregnancy and risk of childhood acute lymphoblastic leukaemia: an observational study. The Lancet Planetary Health 2024, 8: e506-e514. PMID: 38969477, PMCID: PMC11260908, DOI: 10.1016/s2542-5196(24)00121-9.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsRisk of childhood acute lymphoblastic leukemiaChildhood acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaLatino childrenNon-Latino white childrenAssociated with risk of adverse pregnancy outcomesCalifornia Cancer RegistryRisk of acute lymphoblastic leukemiaCalifornia birth recordsRisk of adverse pregnancy outcomesPre-pregnancy periodAssociated with riskBayesian meta-regressionNational Institutes of HealthCancer RegistryCases of childhood acute lymphoblastic leukemiaNational Center for Advancing Translational SciencesAdverse pregnancy outcomesAcute lymphoblastic leukemia casesInstitutes of HealthInvestigation of mechanistic pathwaysBirth recordsGestational weeks 8Pre-pregnancyRacial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatment
2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroupOlder patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChronic myeloid leukemiaTKI adherenceTKI initiationOlder patientsMyeloid leukemiaEnd Results-Medicare databaseTyrosine kinase inhibitor usePolymerase chain reaction testingQuantitative polymerase chain reaction testingOlder patient populationCare of patientsHealth care accessReal-world studyReal-world evidenceLow socioeconomic statusLow-income subsidyFirst yearInfluenza vaccinationInhibitor useWorse survivalTKI treatmentMultivariable analysisPatient populationOptimal monitoringCare accessAssociation between birth characteristics and incidence of pituitary adenoma and craniopharyngioma: a registry-based study in California, 2001–2015
Cote D, Wang R, Morimoto L, Metayer C, Zada G, Wiemels J, Ma X. Association between birth characteristics and incidence of pituitary adenoma and craniopharyngioma: a registry-based study in California, 2001–2015. Cancer Causes & Control 2023, 34: 757-768. PMID: 37225897, PMCID: PMC10363066, DOI: 10.1007/s10552-023-01718-7.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsOlder maternal ageMultivariable logistic regressionNon-Hispanic white individualsHigher maternal educationPituitary adenomasBirth characteristicsMaternal educationSignificant associationMaternal ageOdds ratioNon-Hispanic white raceUnconditional multivariable logistic regressionLogistic regressionParental sociodemographic characteristicsRegistry-based studyPopulation-based studyWhite individualsAdjusted odds ratioEarly-onset cancersNon-Hispanic whitesBirth pluralityIncident casesBlack raceFemale sexHispanic ethnicitySecond malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Wang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSecond malignanciesAcute myeloid leukemiaOlder patientsMyelodysplastic syndromeMyeloproliferative neoplasmsHU usersHigh riskPolycythemia veraEssential thrombocythemiaRisk of SMAML/myelodysplastic syndromeClassical Philadelphia chromosome-negative myeloproliferative neoplasmsImpact of hydroxyureaRetrospective cohort studyUse of hydroxyureaPhiladelphia chromosome-negative myeloproliferative neoplasmsClassical myeloproliferative neoplasmsCumulative incidence probabilityCohort studyCytoreductive therapyPatient characteristicsMedian ageHU useMyeloid leukemiaSecondary myelofibrosisUse of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation
Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIntermediate-risk prostate cancerMixed-effects Poisson regressionPSA testingProstate biopsyProstate cancerEffects Poisson regressionMedicare beneficiariesPoisson regressionAdditional prostate biopsyRetrospective cohort studyProstate MRILocalized prostate cancerRepeat prostate biopsyRate of biopsyRace/ethnicityCensus tract povertyMedian followCohort studyMedian ageMonitoring testsProvider factorsPSA testClinical riskBiopsySociodemographic factors
News
News
- October 03, 2024
Study Reveals Disparities in Colorectal Cancer Screening
- July 03, 2024
Ambient heat during pregnancy linked to increased risk of childhood cancer
- June 05, 2023
Discoveries & Impact (June 2023)
- March 17, 2022
Discoveries & Impact (March 2022)
Get In Touch
Contacts
Email
Academic Office Number
Locations
1 Church Street
Academic Office
Ste 200, Rm 225
New Haven, CT 06510